Format

Send to

Choose Destination
Head Neck Pathol. 2012 Jul;6 Suppl 1:S91-7. doi: 10.1007/s12105-012-0364-5. Epub 2012 Jul 3.

Primary chemotherapy and radiation as a treatment strategy for HPV-positive oropharyngeal cancer.

Author information

1
Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

Abstract

The incidence of human papillomavirus-positive oropharyngeal cancer (HPV/OPSCC) is rapidly increasing, which will represent a major public health burden for decades to come. Although HPV/OPSCC is generally associated with a better prognosis than HPV-negative OPSCC, the survival rate of individuals with higher-risk clinical and pathologic features remains unchanged. Emerging evidence suggests that HPV/OPSCC is pathologically and molecularly distinct from HPV-negative OPSCC. This review focuses on summarizing treatment strategies for HPV/OPSCC by reviewing the peer-reviewed literature and noting ongoing and planned clinical trials in this disease. We also discuss the potential of designing targeted therapy based on the recent genomic findings of HPV/OPSCC.

PMID:
22782228
PMCID:
PMC3394163
DOI:
10.1007/s12105-012-0364-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center